Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with Conditions
On January 6, 2025, Virpax Pharmaceuticals, Inc. announced in a Form 8-K filing that it had received a decision from the Nasdaq Hearings Panel regarding its listing on The Nasdaq Stock Market. The Panel granted the Company’s request to continue its listing, subject to specific conditions outlined in the decision. The Nasdaq Hearings Panel’s decision […]
More Stories
K92 Mining (TSE:KNT) Sets New 52-Week High – Should You Buy?
K92 Mining Inc. (TSE:KNT – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock...
SemiLEDs (NASDAQ:LEDS) Posts Earnings Results
SemiLEDs (NASDAQ:LEDS – Get Free Report) issued its quarterly earnings results on Friday. The semiconductor company reported ($0.08) earnings per...
Hemostemix (CVE:HEM) Stock Price Up 37.9% – Still a Buy?
Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 37.9% on Friday . The company traded as high as...
First Majestic Silver (NYSE:AG) Receives Buy Rating from HC Wainwright
First Majestic Silver (NYSE:AG – Get Free Report) (TSE:FR)‘s stock had its “buy” rating restated by research analysts at HC...
Azincourt Energy (CVE:AAZ) Stock Price Up 50% – Time to Buy?
Shares of Azincourt Energy Corp. (CVE:AAZ – Get Free Report) rose 50% during mid-day trading on Wednesday . The company...
Oceanic Iron Ore (CVE:FEO) Shares Up 66.7% – What’s Next?
Oceanic Iron Ore Corp. (CVE:FEO – Get Free Report)’s stock price traded up 66.7% on Friday . The stock traded...